Left ventricular assist devices: a kidney’s perspective

摘要: The left ventricular assist device (LVAD) has become an established treatment option for patients with refractory heart failure. Many of these experience chronic kidney disease (CKD) due to cardiorenal syndrome type II, which is often alleviated quickly following LVAD implantation. Nevertheless, reversibility CKD remains difficult predict. Interestingly, initial recovery GFR appears be transient, being followed by gradual but significant late decline. elevated compared preimplant status. Larger increases are a proportionally larger Several explanations this decline in renal function after therapy have been proposed, yet definitive answer elusive. Mortality predictors implantation the occurrence either postimplantation acute injury (AKI) or CKD. However, patient outcomes continue improve as becomes more widespread, and adverse events including AKI appear In light growing destination population, it important understand cumulative effects long-term support on function. Additional research passage time required further unravel intricate relationships between kidney.